Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBITDA (2018 - 2025)

Historic EBITDA for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$19.5 million.

  • 10x Genomics' EBITDA rose 6079.17% to -$19.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$61.0 million, marking a year-over-year increase of 6865.48%. This contributed to the annual value of -$61.0 million for FY2025, which is 6865.48% up from last year.
  • Per 10x Genomics' latest filing, its EBITDA stood at -$19.5 million for Q4 2025, which was up 6079.17% from -$32.2 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' EBITDA peaked at $30.1 million during Q2 2025, and registered a low of -$94.8 million during Q3 2023.
  • Its 5-year average for EBITDA is -$37.3 million, with a median of -$40.7 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 47160.84% in 2022, then soared by 17218.06% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' EBITDA stood at -$18.6 million in 2021, then decreased by 24.03% to -$23.1 million in 2022, then crashed by 138.95% to -$55.2 million in 2023, then rose by 9.69% to -$49.8 million in 2024, then surged by 60.79% to -$19.5 million in 2025.
  • Its EBITDA was -$19.5 million in Q4 2025, compared to -$32.2 million in Q3 2025 and $30.1 million in Q2 2025.